Figure 1
Figure 1. Cumulative incidence of secondary solid cancer by disease group among recipients of allogeneic HCT using high-dose Bu-Cy conditioning for AML in CR1 and CML in CP1. The cumulative incidence of solid cancers at 10 years after transplantation was 1.2% for AML and 2.4% for CML patients.

Cumulative incidence of secondary solid cancer by disease group among recipients of allogeneic HCT using high-dose Bu-Cy conditioning for AML in CR1 and CML in CP1. The cumulative incidence of solid cancers at 10 years after transplantation was 1.2% for AML and 2.4% for CML patients.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal